A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2245 participants.
Also called NCT01195662
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,245 participants
- Sponsor
- Registry
-
NCT01195662 -
2010-019798-13
-
- Other papers using this trial's data
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Colombia, Czechia, Denmark, Finland, Germany, Hungary, India, Ireland, Mexico, Poland, Puerto Rico, Romania, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01195662. Randomized; triple masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-05-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo matching Dapagliflozin
- Lead sponsor
- AstraZeneca
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01195662- Content hash
af680eccdffec1f5c68afc37597a97bd87b65c12607aab942242aa77b4bb5d27